Idiopathic Sudden Sensorineural Hearing Loss: Speech Intelligibility Deficits Following Threshold Recovery

pa.ythelady61 shared this article with you from Inoreader Idiopathic Sudden Sensorineural Hearing Loss: Speech Intelligibility Deficits Following Threshold Recovery Via Ear and Hearing - Published Ahead-of-Print Objectives: This retrospective study tests the hypothesis that patients who have recovered from idiopathic sudden sensorineural hearing loss (SSNHL) show deficits in word recognition tasks that cannot be entirely explained by a loss in audibility. Design: We reviewed the audiologic profile of 166 patients presenting with a unilateral SSNHL. Hearing loss severity, degree of threshold recovery, residual hearing loss, and word recognition performance were considered as outcome variables. Age, route of treatment, delay between SSNHL onset and treatment, and audiogram configuration were considered as predictor variables. Results: Severity, residual hearing loss, and recovery were highly variable across patients. While age and onset-treatment delay could not account for the severity, residual hearing loss and recovery in thresholds, configuration of the SSNHL and overall inner ear status as measured by thresholds on the contralateral ear were predictive of threshold recovery. Speech recognition performance was significantly poorer than predicted by the speech intelligibility curve derived from the patient's audiogram. Conclusions: SSNHL is associated with (1) changes in thresholds that are consistent with ischemia and (2) speech intelligibility deficits that cannot be entirely explained by a change in hearing sensitivity. ACKNOWLEDGMENTS: The authors are grateful to William Goedicke and Piotr Marciniak for their technical help and logistic support. This work was supported by the National Institutes of Health—National Institute on Deafness and Other Communication Disorders P50 DC015857 (S.F.M., Project principal investigator). S.F.M. conceived and designed research; M.O. collected the data, A.P. developed software for data acquisition and analysis, M.O. and S.F.M. performed data analysis, and S.F.M., D.B.W., and M.C.L. wrote, edited and revised the article. The authors have no conflicts of interest to disclose. Received June 8, 2020; accepted October 1, 2020 Address for correspondence: Stéphane F. Maison, Eaton-Peabody Laboratories, Massachusetts Eye & Ear, 243 Charles Street, Boston, MA 02114-3096, USA. E-mail: stephane_maison@meei.harvard.edu Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.